DJIA 16,960.57 -123.23 -0.72%
NASDAQ 4,449.56 -22.54 -0.50%
S&P 500 1,978.34 -9.64 -0.48%
market minute promo

Ophthotec (NASDAQ: OPHT)

40.64 0.64 (1.60%)

Quote as of


company name or ticker

Recent Quotes

OPHT $40.64 1.60%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $40.00
Previous Close $40.00
Daily Range $39.50 - $41.07
52-Week Range $22.61 - $47.99
Market Cap $1.4B
P/E Ratio -15.09
Dividend (Yield) $0.00 (0.0%)
Volume 163,657
Average Daily Volume 304,170
Current FY EPS -$2.67

Sector

Industry

Ophthotec (OPHT) Description

Ophthotech Corp is a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the back of the eye with a focus on developing therapeutics for age-related macular degeneration. Website: http://www.ophthotechinc.com/

News & Commentary

Benzinga's Top Initiations

Ohr Pharmaceutical: Questionable Analyst Activity

Phase II Calamity Dooms Ohr's Eye Drops

Why Ophthotech (OPHT) Could Be Positioned for a Surge? - Tale of the Tape

Why Ophthotech (OPHT) Could Be Positioned for a Surge? - Tale of the Tape

Isis Shines, PTC Therapeutics Soars - Analyst Blog

Ophthotech (OPHT) Jumps: Stock Rises 24.5% - Tale of the Tape

Why Ophthotech (OPHT) Stock Is Surging Today

Benzinga's Volume Movers

UPDATE: Ophthotech Announces Has Entered Into Ex-US Licensing, Commercialization Deal with Novartis,

UPDATE: Ophthotech Announces Has Entered Into Ex-US Licensing, Commercialization Deal with Novartis, Will Potentially Get Upfront Payment of $200M, Receive Over $1B

Ophthotech's (OPHT) CEO David Guyer on Q1 2014 Results - Earnings Call Transcript

See More OPHT News...